Growth Hormone Axis · Dosing reference

CJC-1295 (no DAC) dosage

What the human evidence does and does not show, how long studies ran, and the arithmetic for working with vials.

Not approved — research use onlyCPreclinical researchNone established

Full research page Cycle-length evidence Compare Prefer Amiravo on Google

Regulatory status: Not approved — research use only
Human amounts: None established in humans
Route studied: —
Frequency: Not established
Half-life: No half-life data specific to the no-DAC form were identified; the albumin-binding DAC form had an estimated half-life of 5.8 to 8.1 days in healthy adults, and the DAC group is the feature that extends it ^2,3.
Evidence grade: Grade C · Preclinical research
Vial sizes on the market: 2 mg · 5 mg · 10 mg
Other forms seen: —

What CJC-1295 (no DAC) is

CJC-1295 without DAC (also called modified GRF 1-29) is a 29-amino-acid analog of growth hormone-releasing hormone that lacks the albumin-binding group of the long-acting CJC-1295 DAC form. Evidence specific to this form is limited: the published human work concerns the DAC form, and FDA found no safety or effectiveness data for the free base or acetate forms. It has no approved use.

Like other analogs of the first 29 residues of GHRH, the peptide is expected to act on the pituitary GHRH receptor to stimulate growth hormone release, but FDA's 2024 evaluation stated that nonclinical studies were not identified to establish whether the CJC-1295 free base and acetate forms are pharmacologically active ^3. Pharmacology described in the literature belongs to the DAC form and to unmodified GRF(1-29)… How it works →

Key evidence

Jette et al., Endocrinology · 2005 · Animals (rats) and cultured rat pituitary cells
The DAC conjugate CJC-1295 produced about a 4-fold larger GH area under the curve over 2 hours than unmodified hGRF(1-29) and was present in plasma beyond 72 hours; the study did not test the no-DAC peptide itself ^1. ¹
Teichman et al., Journal of Clinical Endocrinology & Metabolism · 2006 · Humans (healthy adults aged 21 to 61)
Dose-dependent increases in GH and IGF-I and an estimated half-life of 5.8 to 8.1 days were reported; FDA reads the clinical references as concerning the DAC form, so these findings are not evidence for the no-DAC form ^2,3. ²
FDA Pharmacy Compounding Advisory Committee evaluation · 2024 · Regulatory review of published literature on CJC-1295-related substances
FDA found no nonclinical or clinical data to assess the safety or effectiveness of CJC-1295 free base or acetate, and noted that safety assessment of the class rested on the DAC forms ^3. ³

All studies on the research page

What the human evidence shows

No approved or established human dose

We searched PubMed and ClinicalTrials.gov and found no human studies that administered CJC-1295 (no DAC). The research described on its page is from cells or animals, and animal amounts do not translate to people.

How long did human studies run?

No human study durations are recorded for CJC-1295 (no DAC).

Cycle-length evidence for CJC-1295 (no DAC)

CJC-1295 (no DAC) draw calculator

Pick the vial strength and the water added, enter an amount, and see the concentration, the units to draw and how many draws the vial holds. Arithmetic only.

1 · Vial strength

sizes on the market

2 · Water added

3 · Amount per draw

4 · Syringe

Your mix

10 mg + 2 mL water = 5 mg/mL

10 units holds 0.5 mg (500 mcg)

Draw toEnter an amount in step 3

U-100 syringe · 100 units = 1 mL

Computed from your inputs. Not a dose or a recommendation.

Compare water volumes for this vialShow

More water = lower concentration = a larger, easier-to-measure draw. Tap a row to use it.

Water	mg/mL	Draw
0.5 mL	20	—
1 mL	10	—
1.5 mL	6.667	—
2 mL	5	—
2.5 mL	4	—
3 mL	3.333	—
5 mL	2	—

Supplies and handling

Lyophilized vial
Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
Sterile diluent
The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
Graduated syringes
Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
Alcohol prep pads
For wiping vial stoppers before each puncture.
Nitrile gloves
Clean gloves for aseptic handling.
Sharps container
Puncture-resistant container for used needles.

Step-by-step reconstitution guide Storage and transport accessories

Storage

Handling of research-grade lyophilized peptide generally follows the supplier's documentation, which should be treated as authoritative. FDA noted that one manufacturer of CJC-1295 acetate bulk substance recommended refrigerated long-term storage, which relates to a bulk specification rather than a regulated product ^3.

Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent: The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed: Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles: Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution: This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed: Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status: Not approved by the FDA for any use; FDA reviewed the CJC-1295 free base and acetate forms for the compounding bulks list in 2024, found no nonclinical or clinical data to assess their safety and effectiveness, and proposed that they not be included ^3,4,7.
United States (FDA): Not FDA-approved; no label for CJC-1295 was found in DailyMed ^7. In December 2024, FDA presented its evaluation of CJC-1295-related bulk drug substances, including the free base and acetate forms, to its Pharmacy Compounding Advisory Committee and proposed that these forms not be included on the 503A bulks list ^3,4. FDA's public safety summary lists CJC-1295 among nominated-but-withdrawn substances ^5.
Sport (WADA): CJC-1295 is named on the WADA Prohibited List 2026 under S2.2.4 (growth hormone releasing factors, GHRH and its analogues), prohibited at all times ^6.

Status varies by country and changes over time. How we describe regulatory status.

CJC-1295 (no DAC) compared with related compounds

Compound	Status	Evidence	Human amounts	Half-life
CJC-1295 (no DAC)	Not approved — research use only	C	None established	No half-life data specific to the no-DAC
CJC-1295 (with DAC)	Not approved — research use only	B	None established	Estimated half-life of 5.8 to 8.1 days a
Ipamorelin	Not approved — research use only	B	None established	Terminal half-life of about 2 hours in h
Sermorelin	Not approved — research use only	B	None established	—
Tesamorelin	FDA-approved	A	FDA label	Mean elimination half-life about 11 minu
GHRP-2	Approved outside the US	B	None established	In a Japanese package insert, the termin

Combinations that include CJC-1295 (no DAC)

Frequently asked questions

What doses of CJC-1295 (no DAC) have been studied in humans?

None that establish an amount. CJC-1295 (no DAC) is not approved anywhere and we found no human studies that administered it. Amiravo does not publish community or vendor figures.

Is there an established CJC-1295 (no DAC) cycle length?

No. We found no human studies that report treatment duration for CJC-1295 (no DAC).

How much bacteriostatic water should be added to a CJC-1295 (no DAC) vial?

There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.

How many units is a given amount on an insulin syringe?

On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.

What is the half-life of CJC-1295 (no DAC)?

No half-life data specific to the no-DAC form were identified; the albumin-binding DAC form had an estimated half-life of 5.8 to 8.1 days in healthy adults, and the DAC group is the feature that extends it ^2,3.

Is CJC-1295 (no DAC) FDA-approved?

Not approved — research use only. Not approved by the FDA for any use; FDA reviewed the CJC-1295 free base and acetate forms for the compounding bulks list in 2024, found no nonclinical or clinical data to assess their safety and effectiveness, and proposed that they not be included ^3,4,7.

References

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology. 2005
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006
Pharmacy Compounding Advisory Committee Meeting, December 4, 2024: FDA presentations on CJC-1295-related bulk drug substances FDA. 2024
Pharmacy Compounding Advisory Committee, December 4, 2024: FDA briefing document and points to consider for CJC-1295-related bulk drug substances FDA. 2024
Substances in Compounding that May Present Significant Safety Risks FDA. 2024
WADA Prohibited List US Food and Drug Administration. 2026
DailyMed drug label search for CJC-1295 (zero labels returned on 22 Oct 2026) DailyMed (NLM). 2026

Last reviewed October 22, 2026 by the Amiravo editorial team. Editorial policy · Report an error